Invasive pneumococcal disease in Canada 2010–2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines
| Autor: | Alejandro Cane, Jelena Vojicic, Bradford D Gessner, Jose A Suaya, Maria Major, Stephane B Dion, Rajeev M. Nepal, Ana Gabriela Grajales |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Serotype Canada Pediatrics medicine.medical_specialty Pneumococcal disease Population Disease Serogroup Pneumococcal Infections Pneumococcal conjugate vaccine Pneumococcal Vaccines 03 medical and health sciences 0302 clinical medicine Age groups 030225 pediatrics medicine Humans 030212 general & internal medicine Child education Aged education.field_of_study Vaccines Conjugate General Veterinary General Immunology and Microbiology business.industry Incidence Public Health Environmental and Occupational Health Infant bacterial infections and mycoses Pneumococcal polysaccharide vaccine Streptococcus pneumoniae Infectious Diseases Child Preschool Molecular Medicine business medicine.drug |
| Zdroj: | Vaccine. 39:3007-3017 |
| ISSN: | 0264-410X 2010-2011 |
| DOI: | 10.1016/j.vaccine.2021.02.069 |
| Popis: | BACKGROUND In 2010-2011, the 13-valent pneumococcal conjugate vaccine (PCV13) replaced the 7- or 10-valent vaccine (PCV7 and PCV10, respectively) in pediatric immunization programs across Canada. For adults aged ≥65 years, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been publicly funded for several decades; PCV13 funding was not recommended in this population, partly due to expected ongoing vaccine-serotype disease decline stemming from herd effects of the pediatric program. Higher-valent PCVs (ie, 15- and 20-valent PCVs [PCV15 and PCV20, respectively]) currently in development may become available in Canada in the coming years. METHODS Using the National Microbiology Laboratory surveillance reports, annual case counts and serotype distribution of invasive pneumococcal disease (IPD) from 2010 to 2017 in Canada were examined to assess the impact of existing programs on PCV13-serotype IPD and determine the proportion of IPD that can potentially be prevented by current and forthcoming higher-valent PCVs. RESULTS The percentages of PCV13-serotype IPD decreased from 55% [1492/2708] in 2010 to 30% [902/3006] in 2017 in all age groups combined, including a decline from 67% [221/331] to 18% [40/219] in children aged |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect